Published in N Engl J Med on March 19, 2002
NIPS to Identify High-risk Patients With ICD (NIPS-ICD) | NCT02373306
Nursing Therapeutics Education and Heart Failure (HF): a Study Protocol (NEHF) | NCT02425488
Arrhythmia Prediction Trial (APRET) | NCT02175836
Non-invasive Ablation of Ventricular Tachycardia | NCT03601832
Stereotactic Non-invasive Ablation of Ventricular Tachycardia | NCT03819504
Preventive VT Substrate Ablation in Ischemic Heart Disease (PREVENT-VT) | NCT04675073
Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med (2008) 5.13
Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation (2007) 5.09
Non-evidence-based ICD implantations in the United States. JAMA (2011) 5.05
Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA (2009) 4.29
Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis (2008) 4.09
Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J (2014) 3.91
Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation (2010) 3.26
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol (2006) 3.20
Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coll Cardiol (2010) 3.18
Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation (2010) 2.94
Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. JACC Cardiovasc Imaging (2008) 2.64
Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death. Circ Cardiovasc Imaging (2012) 2.62
Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation (2009) 2.57
Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005. Circ Arrhythm Electrophysiol (2008) 2.55
"That's like an act of suicide" patients' attitudes toward deactivation of implantable defibrillators. J Gen Intern Med (2008) 2.38
Intra-operative defibrillation testing and clinical shock efficacy in patients with implantable cardioverter-defibrillators: the NORDIC ICD randomized clinical trial. Eur Heart J (2015) 2.38
Clinical utility and safety of a protocol for noncardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantable-cardioverter defibrillators at 1.5 tesla. Circulation (2006) 2.36
Cardiac cell therapy: where we've been, where we are, and where we should be headed. Br Med Bull (2011) 2.26
Sudden death after myocardial infarction. JAMA (2008) 2.24
Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. Heart Rhythm (2013) 2.22
Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J Am Coll Cardiol (2012) 2.18
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol (2013) 2.16
Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A (2006) 2.07
Left ventricular ejection fraction measurements: accuracy and prognostic implications in a large population of patients with known or suspected ischemic heart disease. Int J Cardiovasc Imaging (2008) 2.06
The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol (2006) 2.05
Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death. J Am Coll Cardiol (2012) 2.02
ICD programming. Indian Heart J (2013) 2.00
Redox modification of ryanodine receptors underlies calcium alternans in a canine model of sudden cardiac death. Cardiovasc Res (2009) 2.00
Brief communication: Management of implantable cardioverter-defibrillators in hospice: A nationwide survey. Ann Intern Med (2010) 1.98
Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction. Eur Heart J (2009) 1.92
Beat-to-beat three-dimensional ECG variability predicts ventricular arrhythmia in ICD recipients. Heart Rhythm (2010) 1.85
The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol (2005) 1.83
Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessment. Heart Rhythm (2010) 1.78
Increased left ventricular mass and decreased left ventricular systolic function have independent pathways to ventricular arrhythmogenesis in coronary artery disease. Heart Rhythm (2011) 1.73
Prolonged QRS duration on the resting ECG is associated with sudden death risk in coronary disease, independent of prolonged ventricular repolarization. Heart Rhythm (2011) 1.69
Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol (2012) 1.66
Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease. Circ Arrhythm Electrophysiol (2014) 1.66
Transient local injury current in right ventricular electrogram after implantable cardioverter-defibrillator shock predicts heart failure progression. J Am Coll Cardiol (2009) 1.65
Epidemiology and genetics of sudden cardiac death. Circulation (2012) 1.65
An ECG index of myocardial scar enhances prediction of defibrillator shocks: an analysis of the Sudden Cardiac Death in Heart Failure Trial. Heart Rhythm (2010) 1.65
What evidence do we have to replace in-hospital implantable cardioverter defibrillator follow-up? Clin Res Cardiol (2006) 1.65
"It's like crossing a bridge" complexities preventing physicians from discussing deactivation of implantable defibrillators at the end of life. J Gen Intern Med (2008) 1.63
Safety and efficacy of renal denervation as a novel treatment of ventricular tachycardia storm in patients with cardiomyopathy. Heart Rhythm (2013) 1.63
Gender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: Findings from the National Cardiovascular Data Registry (NCDR). Am Heart J (2015) 1.61
ECG quantification of myocardial scar in cardiomyopathy patients with or without conduction defects: correlation with cardiac magnetic resonance and arrhythmogenesis. Circ Arrhythm Electrophysiol (2008) 1.55
Predictors of early mortality in implantable cardioverter-defibrillator recipients. Europace (2009) 1.55
Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction: Risk Stratification Using Cardiovascular Magnetic Resonance. Circ Cardiovasc Imaging (2016) 1.54
Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy. Ann Thorac Surg (2012) 1.54
Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Heart Rhythm (2010) 1.54
Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators. Circ Heart Fail (2015) 1.53
Sudden cardiac death: epidemiology and risk factors. Nat Rev Cardiol (2010) 1.53
Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc (2010) 1.51
Growth in medicare expenditures for patients with acute myocardial infarction: a comparison of 1998 through 1999 and 2008. JAMA Intern Med (2013) 1.50
Pediatric ICD utilization in the United States from 1997 to 2006. Heart Rhythm (2010) 1.49
Referring physicians' discordance with the primary prevention implantable cardioverter-defibrillator guidelines: a national survey. Heart Rhythm (2012) 1.49
Electrocardiographic Measures and Prediction of Cardiovascular and Noncardiovascular Death in CKD. J Am Soc Nephrol (2015) 1.49
Does defibrillation threshold increase as left ventricular ejection fraction decreases? Europace (2010) 1.47
Systematic review of the incidence of sudden cardiac death in the United States. J Am Coll Cardiol (2011) 1.47
Relation between time from myocardial infarction to enrolment and patient outcomes in the Multicenter UnSustained Tachycardia Trial. Europace (2010) 1.47
SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death. Heart Rhythm (2015) 1.47
Clinical experience with a novel subcutaneous implantable defibrillator system in a single center. Clin Res Cardiol (2011) 1.46
Clinical practice of defibrillator implantation after myocardial infarction: impact of implant time: results from the PreSCD II registry. Europace (2010) 1.45
Experience With the Wearable Cardioverter-Defibrillator in Patients at High Risk for Sudden Cardiac Death. Circulation (2016) 1.44
Iron-Sensitive Cardiac Magnetic Resonance Imaging for Prediction of Ventricular Arrhythmia Risk in Patients With Chronic Myocardial Infarction: Early Evidence. Circ Cardiovasc Imaging (2015) 1.43
Changes in Follow-Up Left Ventricular Ejection Fraction Associated With Outcomes in Primary Prevention Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Device Recipients. J Am Coll Cardiol (2015) 1.43
Arrhythmia risk stratification based on QT interval instability: an intracardiac electrocardiogram study. Heart Rhythm (2013) 1.42
Expanding indications for implantable cardiac defibrillators. N Engl J Med (2002) 1.42
Current pacemaker and defibrillator therapy. Dtsch Arztebl Int (2011) 1.41
Cardiac MRI scar patterns differ by sex in an implantable cardioverter-defibrillator and cardiac resynchronization therapy cohort. Heart Rhythm (2013) 1.40
Selection of high-risk patients for device intervention with the new advances in technology. J Electrocardiol (2012) 1.39
The Wedensky test predicts malignant ventricular arrhythmias after myocardial infarction. Scand Cardiovasc J (2013) 1.39
Therapy for ventricular arrhythmias in structural heart disease: a multifaceted challenge. J Physiol (2016) 1.39
I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging (2007) 1.38
Defibrillator implantations for primary prevention in the United States: Inappropriate care or inadequate documentation: Insights from the National Cardiovascular Data ICD Registry. Heart Rhythm (2015) 1.38
Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. J Am Coll Cardiol (2012) 1.38
Improved Stratification of Autonomic Regulation for risk prediction in post-infarction patients with preserved left ventricular function (ISAR-Risk). Eur Heart J (2008) 1.37
Implementation of guidelines for implantable cardioverter-defibrillator therapy in clinical practice: Which patients do benefit? Neth Heart J (2013) 1.35
Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time? Circulation (2012) 1.34
Prospective observational study of implantable cardioverter-defibrillators in primary prevention of sudden cardiac death: study design and cohort description. J Am Heart Assoc (2013) 1.30
EANM/ESC guidelines for radionuclide imaging of cardiac function. Eur J Nucl Med Mol Imaging (2008) 1.29
Prediction and prevention of sudden cardiac death in heart failure. Heart (2005) 1.29
Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol (2010) 1.28
[Guidelines for the implantation of defibrillators]. Clin Res Cardiol (2006) 1.28
A comprehensive multiscale framework for simulating optogenetics in the heart. Nat Commun (2013) 1.27
Early identification of risk factors for sudden cardiac death. Nat Rev Cardiol (2010) 1.27
The spectrum of epidemiology underlying sudden cardiac death. Circ Res (2015) 1.26
Impact of chronic kidney disease upon survival among implantable cardioverter-defibrillator recipients. J Interv Card Electrophysiol (2004) 1.26
Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA (2013) 1.25
[Guidelines for therapy of chronic heart failure]. Z Kardiol (2005) 1.24
Patient expectations from implantable defibrillators to prevent death in heart failure. J Card Fail (2009) 1.24
Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis (2014) 1.23
Long-term survival after successful inhospital cardiac arrest resuscitation. Am Heart J (2007) 1.22
CKD and sudden cardiac death: epidemiology, mechanisms, and therapeutic approaches. J Am Soc Nephrol (2012) 1.20
Prognostic utility of T-wave alternans in a real-world population of patients with left ventricular dysfunction: the PREVENT-SCD study. Clin Res Cardiol (2011) 1.20
Effect of a psychoeducational intervention on depression, anxiety, and health resource use in implantable cardioverter defibrillator patients. Pacing Clin Electrophysiol (2009) 1.18
Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual Outcomes (2015) 1.18
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med (2012) 8.84
Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med (2004) 7.12
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation (2010) 6.71
Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med (2008) 5.13
Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol (2008) 4.63
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J (2010) 4.13
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation (2004) 3.78
Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol (2008) 3.73
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA (2007) 3.32
Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol (2003) 3.05
Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation (2004) 3.03
Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93
Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation (2007) 2.88
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86
Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol (2011) 2.84
Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm (2009) 2.82
Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation (2004) 2.81
Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy). J Am Coll Cardiol (2013) 2.68
Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol (2009) 2.65
Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD. Pacing Clin Electrophysiol (2004) 2.63
Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation (2004) 2.63
Echocardiographic findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia: new insights from the multidisciplinary study of right ventricular dysplasia. J Am Coll Cardiol (2005) 2.62
Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation (2011) 2.56
Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation (2006) 2.52
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation (2010) 2.49
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2010) 2.41
The influence of public reporting of outcome data on medical decision making by physicians. Arch Intern Med (2005) 2.40
Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation (2008) 2.40
Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol (2008) 2.39
Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation (2008) 2.38
Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol (2006) 2.32
Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. J Am Coll Cardiol (2012) 2.31
Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation (2011) 2.26
Pericardial fat is independently associated with human atrial fibrillation. J Am Coll Cardiol (2010) 2.26
Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol (2012) 2.26
Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol (2003) 2.22
Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation (2002) 2.20
Cardiovascular effects associated with air pollution: potential mechanisms and methods of testing. Inhal Toxicol (2002) 2.19
ECGScan: a method for conversion of paper electrocardiographic printouts to digital electrocardiographic files. J Electrocardiol (2005) 2.17
Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol (2011) 2.15
Mechanisms of ventricular fibrillation initiation in MADIT II patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol (2008) 2.13